0

Biotransformation of Indomethacin by the Fungus Cunninghamella Blakesleeana

Peng Zhang, Li-Hong Lin, Hai-Hua Huang, Hai-Yan Xu, Da-Fang Zhong

Acta Pharmacol Sin. 2006 Aug;27(8):1097-102.

PMID: 16867265

Abstract:

Aim:
To investigate the biotransformation of indomethacin, the first of the newer nonsteroidal anti-inflammatory drugs, by filamentous fungus and to compare the similarities between microbial transformation and mammalian metabolism of indomethacin.
Methods:
Five strains of Cunninghamella (C elegans AS 3.156, C elegans AS 3.2028, C blakesleeana AS 3.153, C blakesleeana AS 3.910 and C echinulata AS 3.2004) were screened for their ability to catalyze the biotransformation of indomethacin. Indomethacin was partially metabolized by five strains of Cunninghamella, and C blakesleeana AS 3.910 was selected for further investigation. Three metabolites produced by C blakesleeana AS 3.910 were isolated using semi-preparative HPLC, and their structures were identified by a combination analysis of LC/MS(n) and NMR spectra. These three metabolites were separated and quantitatively assayed by liquid chromatography-ion trap mass spectrometry.
Results:
After 120 h of incubation with C blakesleeana AS 3.910, approximately 87.4% of indomethacin was metabolized to three metabolites: O-desmethylindomethacin (DMI, M1, 67.2%), N-deschlorobenzoylindomethacin (DBI, M2, 13.3%) and O-desmethyl-N-deschlorobenzoylindomethacin (DMBI, M3, 6.9%). Three phase I metabolites of indomethacin produced by C blakesleeana AS 3.910 were identical to those obtained in humans.
Conclusion:
C blakesleeana could be a useful tool for generating the mammalian phase I metabolites of indomethacin.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP2504327 O-Desmethylindomethacin O-Desmethylindomethacin 2504-32-7 Price
qrcode